As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Zacks Small Cap Research on MSN6d
LEXX: IRB Approval Clears Way for GLP-1 Study #5LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...
With one in eight Americans having taken a GLP-1 already — including 43% of those ... around issues such as expected results, proper injection technique, recognising and managing side effects ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback